文章：

机器人支气管镜在肺癌诊断中的应用

Robotic Bronchoscopy in Lung Cancer Diagnosis

原文发布日期：17 March 2024

DOI: 10.3390/cancers16061179

类型: Article

开放获取: 是

英文摘要：

Background: The widespread use of chest CT has increased the number of detected pulmonary nodules. Nodules with intermediate risk of malignancy warrant further evaluation with PET-CT or sampling. Although sampling with conventional bronchoscopy presents lower complication rates compared to transthoracic needle biopsy (TTNB), it is limited by the inability to reach distal airways. To overcome this shortcoming, a new bronchoscopic technique named robotic bronchoscopy (RB) has emerged. Methods: A literature review was used to clarify the rationale behind RB emergence, describe RB procedure, and summarize data regarding its efficacy and safety. Results: The FDA has approved three RB platforms for clinical use. RB is safe, presenting a mortality and complication rate of 0% and 0–8.1%, respectively. Common complications include pneumothorax (0–5.7%) and minor bleeding (0–3.2%). However, its diagnostic yield remains lower than that of TTNB. Conclusions: RB is a promising bronchoscopic technique that aims to overcome the limitations of conventional bronchoscopy and improve upon the current techniques of guided bronchoscopy for the investigation of pulmonary nodules. Despite the lower complication rate, current evidence suggests a lower diagnostic yield compared to TTNB. Additional studies are required to adequately evaluate the role of RB in the diagnosis of pulmonary nodules.

摘要翻译： 

背景：胸部CT的广泛应用增加了肺结节的检出数量。具有中等恶性风险的结节需通过PET-CT或取样进行进一步评估。尽管传统支气管镜取样相较于经胸穿刺活检（TTNB）并发症发生率较低，但其受限于无法到达远端气道。为克服这一缺陷，一种名为机器人支气管镜（RB）的新型支气管镜技术应运而生。 方法：通过文献综述阐明RB技术出现的理论基础，描述RB操作流程，并总结其有效性与安全性的相关数据。 结果：美国食品药品监督管理局已批准三种RB平台用于临床。RB安全性良好，死亡率和并发症发生率分别为0%和0–8.1%。常见并发症包括气胸（0–5.7%）和轻微出血（0–3.2%）。但其诊断率仍低于TTNB。 结论：RB是一种具有前景的支气管镜技术，旨在克服传统支气管镜的局限性，并改进现有引导支气管镜技术用于肺结节检查。尽管并发症发生率较低，但现有证据表明其诊断率较TTNB更低。需要更多研究来充分评估RB在肺结节诊断中的作用。

原文链接：

Robotic Bronchoscopy in Lung Cancer Diagnosis